Similar articles

• Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

  de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH. de Gast GC, et al. Clin Cancer Res. 2000 Apr;6(4):1267-72. Clin Cancer Res. 2000. PMID: 10778950 Clinical Trial.
• Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.

  Correale P, Marsili S, Sabatino M, Montagnani F, Giorgi G, Francini G. Correale P, et al. Oncol Rep. 2005 Apr;13(4):751-6. Oncol Rep. 2005. PMID: 15756453 Clinical Trial.
• Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.

  Verra N, de Jong D, Bex A, Batchelor D, Dellemijn T, Sein J, Nooijen W, Meinhardt W, Horenblas S, de Gast G, Vyth-Dreese F. Verra N, et al. Eur Urol. 2005 Sep;48(3):527-33. doi: 10.1016/j.eururo.2005.03.031. Epub 2005 Apr 11. Eur Urol. 2005. PMID: 16115526 Clinical Trial.
• Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

  Parton M, Gore M, Eisen T. Parton M, et al. J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
• Adjuvant therapy for malignant melanoma.

  Stoutenburg JP, Schrope B, Kaufman HL. Stoutenburg JP, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823. Expert Rev Anticancer Ther. 2004. PMID: 15485316 Review.